EUVIMEDEUVIMED entdecken
Crossref

Exit Strategy for Treatment of Neovascular Age-Related Macular Degeneration in a Real-World Setting: Wishful Thinking?

Michael Eastline, Sadiq Said, Martina Monika Bosch, Pascal Knecht-Bosch

Klinische Monatsblätter für Augenheilkunde · 01.04.2025 · 242 (04) · 398-404

DOI: 10.1055/a-2511-5899 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Klinische Monatsblätter für Augenheilkunde, erschienen am 01.04.2025. Verfasst von Michael Eastline und 3 weiteren Autor:innen. Beteiligte Einrichtung: Eye Clinic Wettingen, Switzerland. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Wet Macular Degeneration, Macular Degeneration. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

To analyze our outcome for patients with neovascular age-related macular degeneration (nAMD) treated with aflibercept in a treat-and-extend regimen pursuing an exit strategy (with best possible adherence to the “Bern” exit criteria) over 6 years in a real-world setting. The primary objective of the study was to investigate the proportion of patients who were able to achieve and maintain treatment exit.

Methods

This is a retrospective chart review study of treatment-naïve patients diagnosed with nAMD receiving intravitreal aflibercept injections performed at our department with at least 2 years of follow-up visits. The primary outcome was the percentage of patients able to achieve and maintain the treatment exit regarding intravitreal anti-VEGF injections. Further outcome measures were best-corrected visual acuity (BCVA), incidence of recurrence after treatment cessation, duration of therapy, and number and intervals of injections.

Results

There were 31 eyes of 25 patients included in this retrospective study. The observation period was from September 1, 2017 to August 31, 2023. Of all included patient eyes, 22.6% (n = 7) reached exit criteria. Of all the “exit” patients, 28.6% (n = 2) suffered from disease relapse and therapy was restarted at a mean (± SD) of 41.5 ± 12.5 weeks (range: 29 to 54 weeks). Regarding the eyes that met treatment exit, 5 of 31 (16.1%) had no disease recurrence in the observed study period. The median BCVA (Snellen decimal; ± interquartile range: IQR) changed from 0.63 (0.27) at baseline to 0.63 (0.4) in the first year, 0.63 (0.3) in the second year, 0.63 (0.46) in the third year, 0.63 (0.3) in the fourth year, 0.63 (0.4) in the fifth year, and 0.4 (0.04) in the sixth year. The median number of injections (± IQR) per eye in the first year of treatment was 8 (2), in the second year 5 (2), in the third year 5 (2.5), in the fourth year 5 (1), in the fifth year 3 (0.8), and in the sixth year 3 (0). Extension of the treatment interval after the loading phase in weeks was achieved up to a median (± IQR) of 5.8 (4) in the first year, 8.4 (6) in the second year, 8 (5.7) in the third year, 9.4 (5.6) in the fourth year, 7 (6.9) in the fifth year, and 8.4 (3.1) in the sixth year of observation.

Discussion

Our study indicates a lower rate of patients reaching exit criteria with a treat-and-extend regimen compared to clinical study settings, and a similar recurrence rate of nAMD after treatment cessation. Nonadherence to a strict treat-and-extend protocol might influence the result.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsWet Macular DegenerationMacular DegenerationHumansRetrospective StudiesMaleAgedFemaleIntravitreal InjectionsAged, 80 and overTreatment OutcomeVisual AcuityAngiogenesis InhibitorsMiddle AgedRecurrence

Substanzen

afliberceptReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Eye Clinic Wettingen, Switzerland.
  • Department of Ophthalmology, University Hospital Zurich, Switzerland.

Zitieren

APA

Eastline, M., Said, S., Bosch, M. M., & Knecht-Bosch, P. (2025). Exit Strategy for Treatment of Neovascular Age-Related Macular Degeneration in a Real-World Setting: Wishful Thinking?. Klinische Monatsblätter für Augenheilkunde, 242(04), 398-404. https://doi.org/10.1055/a-2511-5899

Vancouver

Eastline M, Said S, Bosch MM, Knecht-Bosch P. Exit Strategy for Treatment of Neovascular Age-Related Macular Degeneration in a Real-World Setting: Wishful Thinking?. Klinische Monatsblätter für Augenheilkunde. 2025;242(04):398-404. doi:10.1055/a-2511-5899

BibTeX
@article{Eastline2025,
  author = {Eastline, Michael and Said, Sadiq and Bosch, Martina Monika and Knecht-Bosch, Pascal},
  title = {Exit Strategy for Treatment of Neovascular Age-Related Macular Degeneration in a Real-World Setting: Wishful Thinking?},
  journal = {Klinische Monatsblätter für Augenheilkunde},
  year = {2025},
  volume = {242},
  number = {04},
  pages = {398--404},
  doi = {10.1055/a-2511-5899}
}
Kostenlos starten →